News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Feb 25, 2015
London, UK, 25 February 2015: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutic
Feb 04, 2015
-Conference Call Today at 8:00 a.m. EST, 1:00 p.m. GMT-
Jan 27, 2015
London, UK, 27 January 2015: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therap
Jan 08, 2015
- All trials on track or ahead of schedule with Phase 3 data now expected by end 2015 -
Jan 08, 2015
- Primary endpoint did not show a statistically significant difference for Sativex compared with placebo in reducing pain-

Pages